Drug Sponsors

NIH launches collaborative program to spur therapeutic development

Friday, May 4, 2012 08:02 AM

The National Institutes of Health (NIH) has unveiled a collaborative program, Discovering New Therapeutic Uses for Existing Molecules, that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

More... »

Abbott, Syngene to open first nutrition R&D center in India

Friday, May 4, 2012 08:01 AM

Abbott, one of India's largest health care companies, is collaborating with Syngene, an Indian CRO and subsidiary of Biocon, to establish its first nutrition R&D center in the country.

More... »

J&J China acquires Guangzhou Bioseal Biotech

Friday, May 4, 2012 08:01 AM

Johnson & Johnson China Investment has acquired Guangzhou Bioseal Biotech, a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. Financial terms of the transaction are not being disclosed. 

More... »

Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio Vaccine

Friday, May 4, 2012 08:00 AM

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Sanofi Pasteur’s, standalone Inactivated Poliovirus Vaccine (IPV) against acute flaccid poliomyelitis (Imovax Polio). Imovax Polio will be added to the country's public immunization program on September 1.

More... »

Synexus aquires Osteomed of Poland

Wednesday, May 2, 2012 04:59 PM

Synexus, a global company that recruits and runs late phase clinical trials, has further strengthened its leadership position in Poland with the acquisition of Warsaw-based Osteomed for an undisclosed sum.

More... »

Novo Nordisk licenses Caisson Biotech drug delivery tech

Wednesday, May 2, 2012 11:33 AM

Caisson Biotech, a subsidiary of Heparinex, has entered into a development and license agreement with Novo Nordisk, a global healthcare company based in Denmark.

More... »

Axerion, AZ collaborate on biologic treatment approach for Alzheimer's

Wednesday, May 2, 2012 10:06 AM

Axerion Therapeutics, a private Connecticut-based biotech, and MedImmune, the global biologics arm of AstraZeneca, have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.

More... »

PRA, Amgen collaborate on biosimilar development program

Wednesday, May 2, 2012 09:18 AM

PRA, a global CRO, has formed a strategic relationship with biotech Amgen for a series of phase III studies to develop several biosimilar drugs on a worldwide basis.

More... »

Mannkind grants Tolero worldwide rights to BTK inhibitors

Monday, April 30, 2012 09:34 AM

Tolero Pharmaceuticals, a Salt Lake City, Utah-based company focused on cancer, has been granted exclusive worldwide rights to develop and commercialize compounds from Valencia, Calif.-based MannKind’s novel BTK (Bruton’s tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

More... »

Astellas and Drais to develop Astellas compound through Telsar

Friday, April 27, 2012 02:13 PM

Astellas Pharma of Tokyo and Drais Pharmaceuticals of Bridgewater, N.J., have entered into a uniquely structured partnership to develop and commercialize an Astellas compound currently in phase IIa study.

More... »